Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2022-07-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "普洛药业股份有限公司2022 年半年度财务报告" which translates to "Puluo Pharmaceutical Co., Ltd. 2022 Semi-Annual Financial Report." It contains detailed financial statements including consolidated balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2022. The report explicitly states it is a half-year report and includes comprehensive financial data and analysis for the period. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-07-27 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding the approval of the 2022 semi-annual report and several internal management system revisions. It includes voting results from the board meeting held on July 27, 2022. The document is short (710 characters) and primarily reports on the board meeting decisions rather than containing the full semi-annual report or detailed financial data. Therefore, it is not the interim/quarterly report itself but an announcement of board resolutions. This fits best under Board/Management Information (MANG) as it concerns board meeting decisions and approvals.
2022-07-27 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 Half-Year Report Summary' (半年度报告摘要) for 普洛药业股份有限公司, indicating it is a summary of the company's interim financial report. It contains financial data for the half-year period, including revenue, net profit, earnings per share, and asset information, which are typical contents of an interim or quarterly report. The document length is 2509 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or a link to a report. There is no indication that this is a full annual report (10-K) or just an announcement of a report publication (RPA). It is not a certification or attestation document, so it does not fall under Regulatory Filings (RNS). Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-07-27 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "普洛药业股份有限公司2022 年半年度报告全文" which translates to "Apeloa Pharmaceutical Co., Ltd. 2022 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, business overview, financial indicators, and operational details for the first half of 2022. The document length is 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes actual financial statements, performance metrics, and management commentary, which are characteristic of an Interim / Quarterly Report. The presence of half-year financial data and detailed analysis confirms it is not a full Annual Report (10-K) but an Interim Report (IR). Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2022
2022-07-27 Chinese
投资者关系管理制度（2022年修订）
Governance Information Classification · 95% confidence The document is titled '投资者关系管理制度' which translates to 'Investor Relations Management System'. It outlines the principles, content, methods, responsibilities, and rules for managing investor relations within the company. The text focuses on governance, communication with investors, compliance with laws and regulations, and internal procedures for investor relations management. There are no financial statements, earnings data, audit results, or announcements of voting results. It is a governance-related document detailing internal rules and practices for investor relations management. Therefore, it fits best under Governance Information (CGR). The document length is 4151 characters, which is sufficient for a detailed governance policy but not a full financial report or announcement.
2022-07-27 Chinese
年报信息披露重大差错责任追究制度（2022年修订）
Governance Information Classification · 95% confidence The document is titled as a system for accountability regarding major errors in annual report information disclosure by 普洛药业股份有限公司. It outlines responsibilities, principles, and penalties related to errors in annual report disclosures. There is no actual financial data, financial statements, or report content present. Instead, it is a governance or procedural document related to the annual report process and disclosure quality control. It does not contain an annual report itself, nor is it an announcement of a report. The content fits best under Governance Information (CGR) as it details internal rules and responsibilities related to annual report disclosures.
2022-07-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.